Injectable GHK-Cu is sold on the strength of research that was never conducted on an injection. Peptide vendors point to decades of copper-peptide literature to back vials marketed for hair, skin and wound repair, but the controlled human studies behind that literature are topical, and the injectable route has essentially none of its own. That gap is the real story here, whatever the molecule’s age.
What the human evidence on GHK-Cu covers
GHK-Cu is the copper complex of the tripeptide glycyl-L-histidyl-L-lysine. It was first identified in 1973 as an activity in human albumin that caused old human liver tissue to synthesize proteins similarly to younger tissue [1]. That finding, from Pickart’s research group, is the origin point for everything that followed: the wound-healing research, the cosmetic creams, and now the injectable products sold under the same name.
A 2008 review from the same researcher reports that controlled studies on aged skin found topical GHK-Cu tightens skin, improves elasticity and firmness, and reduces fine lines, wrinkles, photodamage and hyperpigmentation [2]. That is a real body of controlled human research. It is also, without exception in what I could verify, topical.
The review does not give participant counts for those studies, and I could not trace a specific trial, its sample size, or its treatment length to a citable source in this search. A version of this claim circulates online with a specific “eight to twelve weeks” duration attached. I could not find where that number comes from. Treat it as folklore until someone produces the trial.
No large randomized controlled trial has tested injected GHK-Cu for skin, hair or wound-healing outcomes in humans. This is a plain absence: the study design that would let injectable claims stand on their own evidence, rather than borrowed evidence, simply has not been run.
Bottom line: the human record for GHK-Cu is a topical record. Every injectable claim about GHK-Cu made to a human customer is an extrapolation from a delivery route nobody has tested.
Association, causation and a claim I could not source
Popular write-ups on GHK-Cu describe declining circulating levels with age as though that decline were a well documented, citable clinical finding. I went looking for the study behind it and could not find one that measures plasma copper-peptide concentration across age groups. What I did find, from the 1973 discovery paper, describes GHK as an activity that made old liver tissue behave like younger tissue in an assay, which is not the same thing as a longitudinal or cross-sectional measurement of blood levels by age [1].
That distinction is worth sitting with. An observed association between age and a biomarker, even a widely repeated one, does not establish that restoring the biomarker changes an outcome. The same logic problem shows up with testosterone and with NAD+: a level correlates with youth, so raising the level gets marketed as a fix, and nobody has run the interventional trial that would test whether raising it does anything at all. Until someone runs that trial for GHK-Cu, injecting it to chase a “younger” plasma profile is a bet on an analogy. No effect has been documented. GHK-Cu’s injectable form has no human safety data either, which compounds the problem.
Mechanism: cell and animal work, not injection trials
The mechanistic case for GHK-Cu is genuinely substantial. It is also, again, not evidence about injecting the peptide into a person.
Collagen synthesis. Maquart and colleagues reported in 1988 that the copper complex of GHK stimulates collagen synthesis in cultured fibroblasts, with the effect beginning at concentrations between 10⁻¹² and 10⁻¹¹ M and maximizing around 10⁻⁹ M [3]. That’s a cell-culture finding. It says nothing about skin after an injection.
Wound healing in mice. Wang and coauthors found that GHK-Cu delivered via liposomes increased angiogenesis markers (CD31 and Ki67 staining) and shortened healing time in a mouse scald-wound model, compared with free GHK-Cu [4]. Mice are not people, and a burn wound is not a cosmetic injection site.
Gene expression. A review from Pickart’s group reports that GHK is capable of up- or downregulating at least 4,000 human genes, describing the effect as resetting DNA toward a healthier state [5]. That claim rests on bioinformatic comparison against gene-expression databases, the same class of analysis used across pharmacology to generate drug-repurposing hypotheses. A computational hit is a hypothesis. It is not a completed experiment on a person, and the gene-expression study itself deserves a closer read before anyone treats 4,000 genes as 4,000 promises.
None of these three findings, alone or together, is evidence that injecting GHK-Cu into a person produces the outcome a vendor is selling.
Dosing: published for creams, silent on injections
The literature reports concentrations for topical GHK-Cu formulations, but I could not verify a specific range or application frequency to a citable source in this search, so no number appears here for that. What I can say plainly: animal and cell studies use doses and concentrations that vary widely across experiments, and no published study has established a minimum effective or maximum safe dose for injected GHK-Cu in humans.
That last point deserves weight. Every injectable GHK-Cu product on the market is dosed by guesswork or by analogy to unrelated protocols, because the dose-ranging study that would tell anyone what an effective or safe human injection dose looks like has never been run.
Safety: cytotoxicity data exists, injectable safety data does not
A 2025 systematic review of metal-based coordination complexes by Bezerra and colleagues found that several such complexes, copper-based compounds in particular, produced significant cytotoxicity in cultured cell lines, mainly by triggering apoptosis [6]. That review is about deliberately cytotoxic anticancer copper complexes rather than GHK-Cu, and it comes from cell-culture work rather than human data. But it establishes something true about the underlying chemistry: copper compounds are not automatically benign just because one particular copper peptide has a decent tolerability record on skin. Formulation and dose control are not a footnote. They are the reason a wound-healing peptide and a chemotherapy-adjacent copper complex share a periodic table entry and not much else.
Published safety data on injected GHK-Cu in humans is limited for a specific, traceable reason: essentially all of the controlled human trials in this literature used topical rather than injectable delivery, so injectable-specific safety reporting largely does not exist. Layer on top of that the fact that injectable GHK-Cu sold outside approved topical cosmetic formulations is not FDA-approved, which means its manufacturing answers to none of the quality controls that apply to an approved pharmaceutical.
The safety picture in one line: topical GHK-Cu has a tolerability record. Injectable GHK-Cu has a chemistry lesson and an absence of trials.
Where GHK-Cu injection fits next to tretinoin
Tretinoin is the obvious comparator for anyone weighing a copper peptide against photoaging, and the comparison is not close. A systematic review and meta-analysis by Huang and Lee identified eight randomized controlled trials of topical tretinoin for photodamaged facial skin, covering 1,361 patients, and found significant improvement in both fine and coarse wrinkles compared with vehicle [7].
GHK-Cu, even on its best-documented topical evidence, has nothing close to that trial density. Topical GHK-Cu: strong skin data, thin everywhere else covers the topical case in more depth than this article has room for. For chronic wound care specifically, standard-of-care dressings and established growth-factor therapies have a larger, more direct human trial base than injectable GHK-Cu has ever assembled.
What would change this picture
A randomized, placebo-controlled human trial of injected GHK-Cu, with predefined skin, hair or wound-healing endpoints, would directly test the claims that currently rest on topical trial data and animal mechanism work. Until that trial exists, injectable GHK-Cu is best understood as an extrapolation from topical and preclinical evidence, not as a separately validated intervention in its own right.
If you are weighing a copper-peptide serum against a copper-peptide injection, know what each one is backed by. One has controlled human trials behind it, however thin those trials turn out to be on close inspection. The other has cell cultures, a handful of mice, and a marketing pitch borrowed from the wrong delivery route.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
The human tripeptide GHK-Cu in prevention of oxidative stress and degenerative conditions of aging: implications for cognitive health.. Oxidative medicine and cellular longevity, 2012.
The human tri-peptide GHK and tissue remodeling.. Journal of biomaterials science. Polymer edition, 2008.
Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+.. FEBS letters, 1988.
GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis.. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society, 2017.
GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration.. BioMed research international, 2015.
Preclinical Trials of Cancer Stem Cells Targeted by Metal-Based Coordination Complexes: A Systematic Review.. Pharmaceutics, 2025.
Tretinoin for Photodamaged Facial Skin: Systematic Review and Meta-Analysis of Randomized Controlled Trials.. Dermatology practical & conceptual, 2025.
